NCT05898464View on ClinicalTrials.gov

Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Vaccination; InfectionVaccine Adverse Reaction
Interventions
BIOLOGICAL

Recombinant zoster vaccination

Two doses of recombinant zoster vaccine(Shingrix®), 2 months apart

Trial Locations (2)

03080

Seoul National University Hospital, Seoul

04564

National Medical Center, Seoul

All Listed Sponsors
collaborator

National Medical Center, Seoul

OTHER

collaborator

SMG-SNU Boramae Medical Center

OTHER

lead

Seoul National University Hospital

OTHER